Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study

Background AZD4547 is a potent, oral, highly selective fibroblast growth factor receptor (FGFR) inhibitor in clinical development for treating tumours with a range of FGFR aberrations, including FGFR mutations, amplifications and fusions. Methods This open-label, Phase I, multicentre study (NCT01213...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Saka, Hideo, Kitagawa, Chiyoe, Kogure, Yoshihito, Takahashi, Yasuo, Fujikawa, Koshi, Sagawa, Tamotsu, Iwasa, Satoru, Takahashi, Naoki, Fukao, Taro, Tchinou, Catherine, Landers, Dónal, Yamada, Yasuhide
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2017
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5502072/
https://ncbi.nlm.nih.gov/pubmed/28070720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0416-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados